Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Courtney Eure

Physician Assistant, Medical Martinsville, VA Physician Assistant

NPI 1841689379 CMS profile 10594472

2696 Greensboro Rd, Martinsville, VA 24112

Open in the dashboard

General payments

$12,303

808 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Courtney Eure of Martinsville, VA is reported in the CMS Open Payments database as having received $12,303 across 808 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,837 181
2024 General $2,679 169
2023 General $2,627 174
2022 General $1,876 132
2021 General $2,284 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Courtney Eure
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Courtney Eure were reported at $2,837. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Courtney Eure Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,284 $156 $41–$563 $132
2022 $1,876 $185 $55–$649 $149
2023 $2,627 $199 $58–$717 $160
2024 $2,679 $206 $62–$740 $164
2025 $2,837 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,130 146 payments
  2. Novo Nordisk Inc $1,244 82 payments
  3. Otsuka America Pharmaceutical, Inc. $854 52 payments
  4. Pfizer Inc. $842 82 payments
  5. Lilly USA, LLC $678 46 payments
  6. Amgen Inc. $486 33 payments
  7. AstraZeneca Pharmaceuticals LP $461 24 payments
  8. GlaxoSmithKline, LLC. $429 27 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $377 22 payments
  10. Lundbeck LLC $353 24 payments
  11. Other $4,449 270 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,303 808 payments
Products named General payments · program years 2021–2025
  1. REXULTI $798 48 payments
  2. Ozempic $793 50 payments
  3. RYBELSUS $764 49 payments
  4. VRAYLAR $639 40 payments
  5. UBRELVY $564 39 payments
  6. LINZESS $523 42 payments
  7. QULIPTA $499 29 payments
  8. NURTEC ODT $433 45 payments
  9. XIFAXAN $377 22 payments
  10. TRELEGY ELLIPTA $361 21 payments
  11. Other $11,793 785 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 181 drugs

Part D claims

10,823

Median for Physician Assistant: 241

Drug cost

$975,867

Median for Physician Assistant: $4,110

Branded share of claims

23.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 90 $116,590
Trulicity Dulaglutide Brand 93 $91,996
Januvia Sitagliptin Phosphate Brand 69 $73,853
Mounjaro Tirzepatide Brand 62 $71,520
Jardiance Empagliflozin Brand 73 $65,374
Zenpep Lipase/Protease/Amylase Brand 11 $58,509
Eliquis Apixaban Brand 70 $55,680
Linzess Linaclotide Brand 55 $38,070
Myrbetriq Mirabegron Brand 42 $30,883
Vraylar Cariprazine Hcl Brand 16 $26,589

The 10 drugs with the highest cost, of 181 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$28,372

Of which drugs: $55

Medicare patients

188

Average age 73

Services billed

1,047

134 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 34%
Arthritis 34%
Chronic kidney disease 30%
Atrial fibrillation 21%
COPD 20%
Depression 20%
Ischemic heart disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$185 16 —
REXULTI
$164 — —
XIFAXAN
$125 — —
ZENPEP
$109 11 —
Ozempic
$102 90 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

808 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record